Item 7.01 Regulation FD
On October 1, 2020, representatives of Krystal Biotech, Inc., a Delaware
corporation (the "Company"), made a presentation to the 2020 Virtual debra Care
Conference, which included an update on the Company's GEM-3 clinical trials for
beremagene geperpavec ("B-VEC"). A copy of the Company's presentation is
attached as Exhibit 99.1 hereto and incorporated by reference herein.
In accordance with General Instruction B.2 to Form 8-K, the information
contained in this Current Report, including Exhibit 99.1 attached hereto, is
being "furnished" and not "filed" with the Securities and Exchange Commission
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities under such section. Furthermore, such
information shall not be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, unless specifically identified as being
incorporated therein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description
99.1 Krystal Biotech, Inc. Presentation to the 2020 Virtual debra Care
Conference, dated October 1, 2020
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses